About selumetini b
MEK inhibitor anticancer medicine
Used for
- Treats certain children aged 1 year or older with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas.
Usual adult dose
Not routinely used for adults in its approved indication.
Usual dose in children
25 mg/m² by mouth twice daily, about 12 hours apart; dose is based on body surface area.
Common side effects
- Diarrhea, nausea, vomiting, or abdominal pain
- Rash, dry skin, or acne-like skin changes
- Low energy, fever, or muscle and joint pain
- Swelling around the eyes or hands and feet
Important warnings
- Can affect heart function; heart tests are needed before and during treatment.
- May cause serious eye problems, including retinal changes or vision loss.
- Can cause muscle injury; monitoring may include blood tests.
- Can cause bleeding, severe skin reactions, or harm to an unborn baby.
Pregnancy
May harm an unborn baby. Pregnancy testing and effective contraception are advised during treatment and for one week after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for one week after the last dose.
Interactions
- Strong or moderate CYP3A4 inhibitors can increase selumetinib levels.
- Strong or moderate CYP3A4 inducers can reduce selumetinib levels.
- Avoid grapefruit and Seville oranges, which may affect drug levels.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.